S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
NASDAQ:OTIC

Otonomy Competitors

$2.90
+0.02 (+0.69 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.83
Now: $2.90
$3.00
50-Day Range
$2.88
MA: $4.74
$5.70
52-Week Range
$1.53
Now: $2.90
$6.98
Volume1.33 million shs
Average Volume1.38 million shs
Market Capitalization$140.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31

Competitors

Otonomy (NASDAQ:OTIC) Vs. ACIU, GERN, EVLO, XBIT, RLMD, and FLXN

Should you be buying OTIC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Otonomy, including AC Immune (ACIU), Geron (GERN), Evelo Biosciences (EVLO), XBiotech (XBIT), Relmada Therapeutics (RLMD), and Flexion Therapeutics (FLXN).

AC Immune (NASDAQ:ACIU) and Otonomy (NASDAQ:OTIC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares AC Immune and Otonomy's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AC Immune-392.56%-23.88%-21.85%
Otonomy-14,379.87%-108.75%-54.62%

Analyst Recommendations

This is a summary of recent ratings for AC Immune and Otonomy, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AC Immune00103.00
Otonomy00403.00

AC Immune presently has a consensus target price of $11.00, suggesting a potential upside of 42.30%. Otonomy has a consensus target price of $8.10, suggesting a potential upside of 179.31%. Given Otonomy's higher probable upside, analysts plainly believe Otonomy is more favorable than AC Immune.

Volatility & Risk

AC Immune has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Otonomy has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Insider and Institutional Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 72.3% of Otonomy shares are owned by institutional investors. 16.1% of Otonomy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares AC Immune and Otonomy's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$111.75 million4.96$45.74 million$0.6012.88
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00

AC Immune has higher revenue and earnings than Otonomy. Otonomy is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats AC Immune on 7 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Geron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Otonomy-14,379.87%-108.75%-54.62%
Geron-21,631.02%-43.76%-37.24%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Geron, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Otonomy00403.00
Geron00603.00

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Geron has a consensus price target of $4.00, suggesting a potential upside of 124.72%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Geron.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Geron has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 55.5% of Geron shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 7.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Geron's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00
Geron$460,000.001,201.39$-68,550,000.00($0.36)-4.94

Otonomy has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Geron on 8 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Evelo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Otonomy-14,379.87%-108.75%-54.62%
Evelo BiosciencesN/A-159.17%-88.81%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Evelo Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Otonomy00403.00
Evelo Biosciences03202.40

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Evelo Biosciences has a consensus price target of $18.25, suggesting a potential upside of 56.92%. Given Otonomy's stronger consensus rating and higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Evelo Biosciences.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 7.3% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Evelo Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.36

Otonomy has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Evelo Biosciences on 11 of the 13 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and XBiotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Otonomy-14,379.87%-108.75%-54.62%
XBiotechN/A-7.07%-6.67%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and XBiotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Otonomy00403.00
XBiotech00103.00

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. XBiotech has a consensus price target of $18.00, suggesting a potential downside of 4.26%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than XBiotech.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 31.0% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and XBiotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00
XBiotechN/AN/A$668.63 millionN/AN/A

XBiotech has lower revenue, but higher earnings than Otonomy.

Summary

XBiotech beats Otonomy on 6 of the 11 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Otonomy-14,379.87%-108.75%-54.62%
Relmada TherapeuticsN/A-32.03%-31.41%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Relmada Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Otonomy00403.00
Relmada Therapeutics01202.67

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Relmada Therapeutics has a consensus price target of $63.3333, suggesting a potential upside of 88.16%. Given Otonomy's stronger consensus rating and higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Relmada Therapeutics.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Relmada Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00
Relmada TherapeuticsN/AN/AN/A($2.16)-15.58

Relmada Therapeutics has lower revenue, but higher earnings than Otonomy. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.

Summary

Otonomy beats Relmada Therapeutics on 9 of the 12 factors compared between the two stocks.

Otonomy (NASDAQ:OTIC) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Otonomy and Flexion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Otonomy-14,379.87%-108.75%-54.62%
Flexion Therapeutics-153.90%N/A-53.31%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Otonomy and Flexion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Otonomy00403.00
Flexion Therapeutics011013.00

Otonomy presently has a consensus price target of $8.10, suggesting a potential upside of 179.31%. Flexion Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 82.76%. Given Otonomy's higher possible upside, equities research analysts plainly believe Otonomy is more favorable than Flexion Therapeutics.

Risk & Volatility

Otonomy has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Institutional and Insider Ownership

72.3% of Otonomy shares are owned by institutional investors. 16.1% of Otonomy shares are owned by insiders. Comparatively, 17.0% of Flexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Otonomy and Flexion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Otonomy$600,000.00233.54$-44,670,000.00($1.45)-2.00
Flexion Therapeutics$72.96 million7.49$-149,770,000.00($3.93)-2.82

Otonomy has higher earnings, but lower revenue than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.


Otonomy Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AC Immune logo
ACIU
AC Immune
1.3$7.73+1.8%$554.56 million$111.75 million-8.59
Geron logo
GERN
Geron
1.4$1.78+4.5%$552.64 million$460,000.00-5.09
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.63+3.7%$552.08 millionN/A-4.67Upcoming Earnings
News Coverage
XBiotech logo
XBIT
XBiotech
1.2$18.80+3.6%$550.11 millionN/A1.30
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.66+0.1%$546.71 millionN/A-15.58
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.08+3.0%$546.41 million$72.96 million-3.59News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.20+0.1%$530.44 millionN/A-3.15News Coverage
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$24.87+3.2%$529.86 million$13.80 million-12.01Upcoming Earnings
News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.7$40.40+12.3%$526.41 million$195.89 million115.43News Coverage
Gap Up
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.37+3.9%$526.00 million$56.50 million0.00Decrease in Short Interest
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$10.71+6.4%$522.17 million$15.98 million-1.89Upcoming Earnings
Unusual Options Activity
News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.49+0.4%$518.16 million$58.12 million-16.85Increase in Short Interest
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$9.16+3.2%$514.77 million$1.98 million-5.52Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.51+2.8%$512.19 million$109.33 million-2.58Upcoming Earnings
News Coverage
Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.53+4.5%$510.22 million$335 million-1.19Earnings Announcement
Analyst Revision
News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$13.03+1.8%$510.02 millionN/A-6.39
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.86+2.8%$508.55 millionN/A-14.00
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$19.92+4.7%$507.84 millionN/A-4.18
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.40+1.9%$507.00 million$1.19 million-6.42Upcoming Earnings
SIGA
SIGA Technologies
0.3$6.55+0.5%$506.97 million$26.74 million16.38Upcoming Earnings
Athenex logo
ATNX
Athenex
1.6$5.38+1.5%$502.16 million$101.23 million-3.68Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Affimed logo
AFMD
Affimed
1.6$5.67+4.2%$500.81 million$23.96 million-9.61
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.88+4.0%$498.19 million$25 million-18.28News Coverage
89bio logo
ETNB
89bio
1.6$24.84+0.6%$493.79 millionN/A-4.92
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$16.13+0.1%$493.48 millionN/A-4.65Upcoming Earnings
News Coverage
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$17.91+5.0%$486.92 million$18.15 million-4.21
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.43+1.9%$482.53 millionN/A-9.64
Homology Medicines logo
FIXX
Homology Medicines
1.6$10.55+6.7%$477.54 million$1.67 million-3.86Analyst Report
News Coverage
Evolus logo
EOLS
Evolus
1.1$14.02+10.8%$473.16 million$34.92 million-6.91Analyst Report
Gap Down
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.9$18.37+0.6%$472.42 millionN/A-5.34
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.10+2.2%$472.01 million$59.22 million40.50Upcoming Earnings
Unusual Options Activity
News Coverage
DURECT logo
DRRX
DURECT
1.4$2.31+3.5%$469.34 million$29.56 million-46.19Upcoming Earnings
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$20.05+0.2%$468.63 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.89+20.7%$458.21 million$36.63 million-5.75High Trading Volume
News Coverage
Gap Down
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.5$13.99+6.6%$457.01 millionN/A-4.86Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.22+4.5%$455.89 million$6.68 million-5.08News Coverage
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.3$13.13+5.8%$455.10 millionN/A0.00Analyst Upgrade
Increase in Short Interest
News Coverage
Gap Down
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.5$19.27+11.6%$447.33 millionN/A0.00Upcoming Earnings
News Coverage
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.45+0.0%$434.66 million$49.65 million-2.04News Coverage
Gap Down
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$17.59+6.5%$431.92 millionN/A-6.93News Coverage
Gap Down
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.22+2.1%$426.69 million$111.39 million30.14
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.70+3.5%$416.35 million$28.91 million-6.17
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.36+0.0%$412.71 million$6.07 million-3.52Earnings Announcement
UroGen Pharma logo
URGN
UroGen Pharma
1.9$19.73+3.7%$412.30 million$20,000.00-3.08News Coverage
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$3.96+1.0%$410.45 million$102.31 million5.91
Verastem logo
VSTM
Verastem
1.8$2.38+2.5%$404.06 million$17.46 million-1.69
Immunome logo
IMNM
Immunome
1.1$38.16+4.7%$402.28 millionN/A0.00Increase in Short Interest
XOMA logo
XOMA
XOMA
1.8$36.20+2.5%$399.00 million$18.37 million-32.61Upcoming Earnings
Decrease in Short Interest
News Coverage
Athersys logo
ATHX
Athersys
1.3$2.01+8.0%$397.38 million$5.63 million-5.43
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.96+2.5%$396.03 million$272.30 million-6.96Earnings Announcement
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.